RBC Capital raised the firm’s price target on Legend Biotech (LEGN) to $77 from $75 and keeps an Outperform rating on the shares. The company’s Q2 earnings beat reflects the continued strong demand and successful manufacturing for Carvykti that can drive sustainable growth for the franchise, the analyst tells investors in a research note. RBC adds that it continues to expect growth in the U.S., with further acceleration ex-US, and sees a number of tailwinds for the company, including pull through of 5-year OS data.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LEGN:
- Positive Outlook for Legend Biotech: Strong Sales Growth and Strategic Advancements Drive Buy Rating
- Legend Biotech’s Strategic Growth and Record Sales Drive Buy Rating
- Strong Buy Rating for Legend Biotech Driven by CARVYKTI’s Market Success and Strategic Expansions
- Legend Biotech’s Q2 2025: Strong CARVYKTI Sales and Strategic Growth
- UnitedHealth Stock (UNH) Tumbles 50% YTD; Here’s How to Buy the Dip Without the Risk